Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 4;2(4):654-664.
doi: 10.1016/j.ekir.2017.02.019. eCollection 2017 Jul.

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

Radko Komers  1 , Debbie S Gipson  2 , Peter Nelson  3 , Sharon Adler  4 , Tarak Srivastava  5 , Vimal K Derebail  6 , Kevin E Meyers  7 , Pablo Pergola  8 , Meghan E MacNally  1 , Jennifer L Hunt  1 , Alvin Shih  1 , Howard Trachtman  9
Affiliations

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

Radko Komers et al. Kidney Int Rep. .

Abstract

Introduction: Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administration-approved therapies for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in the pathophysiology of podocyte disorders, including FSGS. Sparsentan is a first-in-class, orally active, dual-acting angiotensin receptor blocker (ARB) and highly selective endothelin Type A receptor antagonist. This study is designed to evaluate whether sparsentan lowers proteinuria compared with an ARB alone and has a favorable safety profile in patients with FSGS.

Methods: DUET is a phase 2, randomized, active-control, dose-escalation study with an 8-week, fixed-dose, double-blind period followed by 136 weeks of open-label sparsentan treatment. Patients aged 8 to 75 years with primary FSGS will be randomized to treatment with sparsentan or irbesartan for 8 weeks.

Results: The primary efficacy objective is to test the hypothesis that sparsentan over the dose range (200 mg, 400 mg, or 800 mg daily) is superior to irbesartan (300 mg daily) in decreasing the urinary protein-to-creatinine ratio (UPC) from baseline to 8 weeks postrandomization. As secondary objectives, the trial will evaluate the proportion of patients who achieve prespecified targets of UPC reduction, changes in laboratory and quality-of-life indices, and detailed safety analysis. Analyses will be conducted at the end of the double-blind (week 8) and open-label (week 144) periods.

Discussion: This study will provide important evidence on whether dual ARB and endothelin blockade may be an effective therapeutic strategy for FSGS and may provide the rationale for next-phase trials.

Keywords: endothelin receptor antagonist; focal segmental glomerulosclerosis; irbesartan; nephrotic syndrome; proteinuria; sparsentan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
DUET study design and analysis periods. RASI, renin−angiotensin system inhibitor.
Figure 2
Figure 2
Progressive dosing cohorts for the DUET study. The study will progress only after safety review by the data monitoring committee (DMC).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. D’Agati V.D., Kaskel F.J., Falk R.J. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365:2398–2411. - PubMed
    1. Sadowski C.E., Lovric S., Ashraf S. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26:1279–1289. - PMC - PubMed
    1. Reiser J., Nast C.C., Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014;21:417–421. - PMC - PubMed
    1. Kronbichler A., Leierer J., Oh J. Immunologic changes implicated in the pathogenesis of focal segmental glomerulosclerosis. Biomed Res Int. 2016;2016:2150451. - PMC - PubMed
    1. Rosenberg A.Z., Naicker S., Winkler C.A. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol. 2015;11:150–160. - PubMed